Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

Seagen

Status

Treatments: Drug: ladiratuzumab vedotin

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT06362590

LV-SPIND-001

Details and patient eligibility

About

The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.

Sex

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria